Synthetic Two-Component System for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting aberrant signaling pathways often suffer from toxicity and resistance due to their inability to differentiate between normal and tumorigenic signaling levels, and limited options for inducing synthetic lethality in cancer cells.
Innovation Solution
A method involving the administration of synthetic signaling proteins that couple the detection of oncogenic signals to the release of therapeutic agents within cancerous cells, using fusion proteins with a protease connected to a phosphotyrosine binding (PTB) domain and an SH2 domain, specifically targeting hyperactive receptor tyrosine kinases like ErbB, to release anti-cancer therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacological approaches block tumor-promoting signals, then cancer therapy is achieved, but toxicity occurs from inhibition of normal physiological processes
Solution Approach 1:
The patent applies local quality by designing fusion proteins with specific domain compositions that are selectively activated only in cancer cells with aberrant signaling. The first fusion protein contains a protease and phosphotyrosine binding domain, while the second contains an SH2 domain and therapeutic agent, creating localized functional differences that enable selective cancer cell targeting without affecting normal cells
Solution Approach 2:
The patent uses fusion proteins as intermediaries that mediate between the detection of oncogenic signals and the release of therapeutic agents. These fusion proteins act as molecular mediators that translate aberrant signaling events into selective therapeutic responses, bridging the gap between signal detection and drug delivery while avoiding direct toxicity to normal cells
2Reliability
If pharmacological approaches inhibit signaling pathways, then tumor growth is blocked, but resistance develops due to target site mutation or compensatory mutations
Solution Approach 1:
The patent implements feedback mechanisms where the fusion proteins continuously monitor signaling pathway activity through their binding domains (phosphotyrosine binding and SH2 domains). When aberrant signaling is detected, the system automatically triggers therapeutic agent release, creating a closed-loop feedback system that adapts to changing cancer cell signaling states and prevents resistance development
Solution Approach 2:
The patent applies dynamics by designing a system where fusion proteins can transition between different functional states based on signaling conditions. The protease activity and domain interactions are dynamically regulated by the level of oncogenic signaling, allowing the therapy to adapt in real-time to cancer cell responses and prevent resistance through continuous adjustment
3Reliability
If synthetic lethality is induced by blocking protein functions, then cancer cells are selectively killed, but the small set of known synthetic dependencies limits therapy options
Solution Approach 1:
The patent applies universality by designing a platform technology where fusion proteins can be configured with different domain combinations to target multiple signaling pathways. The modular architecture allows the same basic fusion protein structure to be adapted for different cancer types and signaling abnormalities, providing versatile therapy options beyond limited synthetic dependencies
Solution Approach 2:
The patent uses segmentation by dividing the therapeutic system into separate functional modules: signaling detection domains (PTB, SH2), catalytic domains (proteases), and therapeutic payload domains. This segmentation allows independent optimization and recombination of modules to create customized therapies for different cancer types, expanding therapy options through modular assembly
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for targeted and specific delivery of therapeutic agents to cancer cells, reducing toxicity and overcoming resistance by selectively releasing anti-cancer agents in response to aberrant signaling, thereby achieving effective tumor response.
Implementation Method 1
a first fusion protein comprising a protease connected to a phosphotyrosine binding (PTB) domain capable of binding to a phosphorylated tyrosine residue on the receptor tyrosine kinase
Implementation Method 2
cleavage of the substrate at the cleavage site by the protease of the first fusion protein releases the anti-cancer therapeutic agent from the second fusion protein
Implementation Method 3
a second fusion protein comprising an SH2 domain connected to i) a substrate comprising a cleavage site recognized by the protease and ii) an anti-cancer therapeutic agent
Data Source
AI summary
Compositions and methods for targeted treatment of cancer are disclosed. In particular, the invention relates to methods of targeting anti-cancer therapy to cells exhibiting aberrant signaling associated with cancer pathogenesis by administering synthetic signaling proteins that couple detection of an oncogenic signal to release of therapeutic agents into cancerous cells.